About the Journal

Translational Cancer Research

Aims and Scope

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

TCR is an international peer-reviewed journal, published by AME Publishing Company. It is published bimonthly (Jun. 2012 - Aug. 2019), monthly (Sep. 2019 - ) and openly distributed worldwide.

Information for Authors

TCR is a member of the International Committee of Medical Journal Editors (ICMJE) and follows the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal and the Committee on Publication Ethics (COPE)'s guidelines.

Manuscripts submitted must be original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

Database

  • Science Citation Index Expanded (SCIE), 2018 Impact Factor 1.07
  • Scopus
  • Google Scholar

Manuscripts Turnaround Time:

  • External peer review: 1-2 months
  • Revision time: 2-4 weeks
  • Publication Ahead of Print: within 1-2 months after being accepted
  • Formal publication: within 1-3 months after being accepted. Original Articles are listed as priority.

TCR is the Official Publication of:

Open Access Statement

This journal is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for everyone to read, download, copy and distribute as defined by the applied license.

Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:

  • this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
  • the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
  • no derivatives including remix, transform, or build upon the material was allowed for distribution.

The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/

Copyright

For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to TCR, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

For any inquiry/special circumstance on the copyright, commercial usage or adaptation of TCR articles, please contact: permissions@amegroups.com

For reprint order, please contact: sales@amegroups.com

Editorial Office

Email: tcr@amepc.org
Phone: +86 20 66355775

Publisher Information

TCR is published by AME Publishing Company.
Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.

 

Updated on March 12, 2020